ABSTRACT
Introduction: High grade gliomas continue to represent a group of cancers that are difficult to control with current cytotoxics and antiangiogenics. With tumor angiogenesis representing a critical mechanism, there is an unmet need for novel types of treatment that can hone in on this important pathway of tumorigenesis.
Areas covered: Virotherapy is a promising modality of cancer treatment that is defined by genetic manipulation of a virus to preferentially target neoplastic cells. VB-111 (ofranergene obadenovec) is a genetically modified adenovirus that is designed to selectively target tumor-associated endothelial cells. Utilizing PubMed and MEDLINE® databases, we identified key preclinical and clinical data pertaining to VB-111. We then reviewed ClinicalTrials.gov to determine the status of ongoing research.
Expert opinion: Demonstrating safety and showing signs of efficacy in early phase clinical trials, VB-111 is being studied in combination with and without bevacizumab in a large phase 3 trial for recurrent glioblastoma. Given the data, VB-111 is a unique viral-mediated, antiangiogenic approach that has significant potential to make an impact in the field of oncology and neuro-oncology. We agree with the continued study of this agent in expanded and randomized cohorts to determine if VB-111 can indeed impact survival in glioblastoma.
Declaration of interest
VBL reviewed and agreed on the publication of this manuscript, also providing access to for the paper. KB Peters has acted on the advisory board for Novocure and Agios. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.